danube trial: durvalumab alone or with tremelimumab for metastatic bladder cancer
Published 3 years ago • 186 plays • Length 4:38Download video MP4
Download video MP3
Similar videos
-
2:31
durvalumab plus tremelimumab or durvalumab monotherapy in metastatic urothelial carcinoma
-
3:02
danube: pd-l1 as a predictor of survival in patients with muc
-
3:48
poseidon: durvalumab /- tremelimumab chemo in 1l mnsclc
-
1:07
dr. balar on impact of durvalumab plus tremelimumab in bladder cancer
-
3:20
updates on the danube, keynote-361 and javelin studies
-
3:56
dose escalation of durvalumab tremelimumab in patients with metastatic urothelial cancer
-
1:00
trial of durvalumab for bladder cancer
-
8:08
durvalumab /- tremelimumab versus chemotherapy for first-line advanced urothelial carcinoma
-
6:56
update on durvalumab for metastatic bladder cancer
-
2:10
poseidon: 4 year follow up of durvalumab and tremelimumab in nsclc
-
2:55
highlights of durvalumab for advanced bladder cancer
-
5:14
combination trials in advanced bladder cancer
-
2:13
inspire: bladder-sparing chemort with durvalumab in ln urothelial cancer
-
1:43
dr. sonpavde discusses a study of fixed-dose durvalumab and tremelimumab in urothelial carcinoma
-
1:06
the mechanism of action of durvalumab in the treatment of urothelial bladder cancer
-
1:33
dr. balar on results of durvalumab plus tremelimumab in bladder cancer
-
2:03
durvalumab fda approval for bladder cancer
-
2:12
dutreneo: durvalumab and tremelimumab vs chemo
-
1:08
dr. rafii on durvaluamb in patients with urothelial bladder cancer